Treatment with the PPARγ Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats
Autor: | Nobuhisa Matsushita, Tomoya Kinouchi, Shinji Nagahiro, Kenji Shimada, Keiko T. Kitazato, Yoshitaka Kurashiki, Junichiro Satomi, Masataka Sata, Kenji Yagi, Yoshiteru Tada |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
medicine.medical_specialty PPARγ Neurogenesis Ischemia Peroxisome proliferator-activated receptor Pparγ agonist Brain ischemia 03 medical and health sciences 0302 clinical medicine Post-stroke treatment Internal medicine medicine Resident stem cells Bone marrow-derived stem cells chemistry.chemical_classification business.industry General Neuroscience medicine.disease Neural stem cell 030104 developmental biology Endocrinology medicine.anatomical_structure chemistry Cancer research Neurology (clinical) Bone marrow Cardiology and Cardiovascular Medicine business Pioglitazone 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Translational Stroke Research. 9:306-316 |
ISSN: | 1868-601X 1868-4483 |
DOI: | 10.1007/s12975-017-0577-8 |
Popis: | Neurogenesis is essential for a good post-stroke outcome. Exogenous stem cells are currently being tested to promote neurogenesis after stroke. Elsewhere, we demonstrated that treatment with the PPARγ agonist pioglitazone (PGZ) before cerebral ischemia induction reduced brain damage and activated survival-related genes in ovariectomized (OVX) rats. Here, we tested our hypothesis that post-ischemia treatment with PGZ inhibits brain damage and contributes to neurogenesis via activated stem cells. Bone marrow (BM) cells of 7-week-old Wistar female rats were replaced with BM cells from green fluorescent protein-transgenic (GFP+BM) rats. Three weeks later, they were ovariectomized (OVX/GFP+BM rats). We subjected 7-week-old Wistar male and 13-week-old OVX/GFP+BM rats to 90-min cerebral ischemia. Male and OVX/GFP+BM rats were divided into two groups, one was treated with PGZ (2.5 mg/kg/day) and the other served as the vehicle control (VC). In both male and OVX/GFP+BM rats, post-ischemia treatment with PGZ reduced neurological deficits and the infarct volume. In male rats, PGZ decreased the mRNA level of IL-6 and M1-like macrophages after 24 h. In OVX/GFP+BM rats, PGZ augmented the proliferation of resident stem cells in the subventricular zone (SVZ) and the recruitment of GFP+BM stem cells on days 7–14. Both types of proliferated stem cells migrated from the SVZ into the peri-infarct area. There, they differentiated into mature neurons, glia, and blood vessels in association with activated Akt, MAP2, and VEGF. Post-ischemia treatment with PGZ may offer a new avenue for stroke treatment through contribution to neuroprotection and neurogenesis. |
Databáze: | OpenAIRE |
Externí odkaz: |